Trial for PARP-Inhibitor for Germ-Line in BRCA1 & 2 | Response Rate Doubled Comparing Talazoparib

Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1 & 2 | Response Rate Doubled Comparing Talazoparib at Annual Meeting 2018